StemCells Inc. is a top biotech company developing stem cell-based therapies. They have a deep pipeline that includes already ongoing trials for a variety of diseases. I invited company leadership to do an interview and they graciously accepted. Below is the interview with CFO Greg Schiffman (picture at left from LinkedIn) including what I thought […]
Interview with StemCells Inc. leadership on hot topics Read More »
What are the most interesting questions for the stem cell field in 2014 right now? What’s on your mind? I’m not going to give this deep thought, but rather just list those questions bouncing around at the moment in no particular order. You can see a lot of translational/clinical things are on my mind. I’ve
Key questions for stem cell field bouncing around on a Friday morning Read More »
This post is a tribute to the late Dr. Yoshiki Sasai (笹井芳樹). If you would like your name added to this tribute please let me know. You are also welcome to add your own tributes in the comments. In an era when the emerging field of regenerative medicine is just beginning to take wing, we
Stem Cell Community Tribute to Yoshiki Sasai (笹井芳樹) Read More »
ISSCR and I held a short essay contest for a free registration to ISSCR 2014 in Vancouver. The winning piece was written by student Mohamed Gatie, but there was a great 2nd place essay by Sherry Hikita that deserved acknowledgment. I’m publishing that essay below and Sherry will be receiving a free signed copy of my book and a free stem cell
Great 2nd Place ISSCR Essay Related to Vision and Stem Cells Read More »
What happens if we start using induced pluripotent stem (iPS) cells clinically in humans? A cool new paper recently came out that gets us closer to being able to predict an answer. It’s an important question as iPS cell-derived cellular products are getting closer to clinical use. For example, the first iPS cell-based clinical trial
Cool, encouraging new preclinical study on monkey iPS cells Read More »
What does the future hold for CIRM? I asked former CIRM Board Chair and Prop 71 leader, Robert Klein, about that and more in the interview below. He also says some particularly exciting clinical trial and other developments in the stem cell field are coming soon. What got you excited for the very first time
Interview with Robert Klein on CIRM’s Future Read More »
Stem cell biotech, Advanced Cell Technology (ACT; stock symbol ACTC), has started off 2014 with indications that it is in a phase of rapid evolution. Some changes, such as today’s announced departure of now former CEO Gary Rabin (see my 2013 interview with him here), are already in the public domain, but other big developments
Big Changes Unfolding at Advanced Cell Technology (ACTC) Read More »
The below is an excerpt from my book, Stem Cells: An Insider’s Guide. I hope you enjoy this excerpt and the book, which I think is a really good deal at under $27 paperback or under $17 for E-book version. Having our innovation and ethics too In the stem cell field you can have it
Book Excerpt: Stem Cell For-Profit Good Citizen Biotechs Read More »
In the interview below I talk with Dr. Masayo Takahashi, who is leading a team conducting the first ever in-human clinical study based on iPS cells. The work began with patient enrollment on Aug. 1, 2013 in Japan. Masaya Takahashi background 1. Can you tell us a bit about your background? As an M.D./Ph.D. and
Masayo Takahashi Interview on iPS cells, clinical studies, & more Read More »
Every year I do predictions for the stem cell field for the coming year. You can see my full post on my predictions for this year here. Stay tuned soon for my predictions for 2014. How’d I do for 2013 with my predications? Each prediction for this year that I made last year is bolded
How’d stem cell predictions for 2013 fare? Read More »